1
|
Hundemer GL, Leung AA, Kline GA, Brown JM, Turcu AF, Vaidya A. Biomarkers to Guide Medical Therapy in Primary Aldosteronism. Endocr Rev 2024; 45:69-94. [PMID: 37439256 PMCID: PMC10765164 DOI: 10.1210/endrev/bnad024] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 06/23/2023] [Accepted: 07/11/2023] [Indexed: 07/14/2023]
Abstract
Primary aldosteronism (PA) is an endocrinopathy characterized by dysregulated aldosterone production that occurs despite suppression of renin and angiotensin II, and that is non-suppressible by volume and sodium loading. The effectiveness of surgical adrenalectomy for patients with lateralizing PA is characterized by the attenuation of excess aldosterone production leading to blood pressure reduction, correction of hypokalemia, and increases in renin-biomarkers that collectively indicate a reversal of PA pathophysiology and restoration of normal physiology. Even though the vast majority of patients with PA will ultimately be treated medically rather than surgically, there is a lack of guidance on how to optimize medical therapy and on key metrics of success. Herein, we review the evidence justifying approaches to medical management of PA and biomarkers that reflect endocrine principles of restoring normal physiology. We review the current arsenal of medical therapies, including dietary sodium restriction, steroidal and nonsteroidal mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and aldosterone synthase inhibitors. It is crucial that clinicians recognize that multimodal medical treatment for PA can be highly effective at reducing the risk for adverse cardiovascular and kidney outcomes when titrated with intention. The key biomarkers reflective of optimized medical therapy are unsurprisingly similar to the physiologic expectations following surgical adrenalectomy: control of blood pressure with the fewest number of antihypertensive agents, normalization of serum potassium without supplementation, and a rise in renin. Pragmatic approaches to achieve these objectives while mitigating adverse effects are reviewed.
Collapse
Affiliation(s)
- Gregory L Hundemer
- Department of Medicine, Division of Nephrology, University of Ottawa, Ottawa, ON K1H 8L6, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
| | - Alexander A Leung
- Department of Medicine, Division of Endocrinology and Metabolism, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
| | - Gregory A Kline
- Department of Medicine, Division of Endocrinology and Metabolism, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
| | - Jenifer M Brown
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Adina F Turcu
- Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA
| | - Anand Vaidya
- Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
2
|
H Brandt-Jacobsen N, Johansen ML, Rasmussen JJ, Dalsgaard M, Kumler T, Faber J, Rossignol P, Schou M, Kistorp C. Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial. BMC Cardiovasc Disord 2023; 23:175. [PMID: 37003987 PMCID: PMC10064675 DOI: 10.1186/s12872-023-03183-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 03/14/2023] [Indexed: 04/03/2023] Open
Abstract
BACKGROUND Early heart failure prevention is central in patients with type 2 diabetes, and mineralocorticoid receptor antagonists (MRAs) have shown to improve prognosis. We investigated the effect of high-dose MRA, eplerenone, on cardiac function and structure in patients with type 2 diabetes and established or increased risk of cardiovascular disease but without heart failure. METHODS In the current randomized, placebo-controlled clinical trial, 140 patients with high-risk type 2 diabetes were randomized to high-dose eplerenone (100-200 mg daily) or placebo as add-on to standard care for 26 weeks. Left ventricular systolic and diastolic function, indexed left ventricular mass (LVMi), and global longitudinal strain (GLS) were assessed using echocardiography at baseline and after 26 weeks of treatment. RESULTS Of the included patients, 138 (99%) had an echocardiography performed at least once. Baseline early diastolic in-flow velocity (E-wave) indexed by mitral annulus velocity (e') was mean (SD) 11.1 (0.5), with 31% of patients reaching above 12. No effect of treatment on diastolic function was observed measured by E/e' (0.0, 95%CI [-1.2 to 1.2], P = 0.992) or E/A (-0.1, 95%CI [-0.2 to 0.0], P = 0.191). Mean left ventricular ejection fraction (LVEF) at baseline was 59.0% (8.0). No improvement in systolic function was observed when comparing groups after 26 weeks (LVEF: 0.9, 95%CI [-1.1 to 2.8], P = 0.382; GLS: -0.4%, 95%CI [-1.5 to 0.6], P = 0.422), nor in LVMi (-3.8 g/m2 95%CI [-10.2 to 2.7], P = 0.246). CONCLUSION In the present echo sub-study, no change in left ventricular function was observed following high-dose MRA therapy in patients with type 2 diabetes when evaluated by conventional echocardiography. TRIAL REGISTRATION Date of registration 25/08/2015 (EudraCT number: 2015-002,519-14).
Collapse
Affiliation(s)
- Niels H Brandt-Jacobsen
- Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Marie Louise Johansen
- Department of Endocrinology-Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark
| | - Jon J Rasmussen
- Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
| | - Morten Dalsgaard
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark
| | - Thomas Kumler
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark
| | - Jens Faber
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Endocrinology-Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark
| | - Patrick Rossignol
- Université de Lorraine, Nancy, France
- Department de Défaillance Cardiovasculaire Aiguë et Chronique, L'Institut National de la Santé et de la Recherche Médicale (URM-S 116), Nancy, France
- Centre Hospitalier Régional Universitaire, Nancy, France
- French Clinical Research Infrastructure Network Investigation Network Initiative - Cardiovascular and Renal Clinical Trialists, Nancy, France
- Centre d'Investigation Clinique Plurithématique 1433, L'Institut National de la Santé et de la Recherche Médicale, Nancy, France
| | - Morten Schou
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark
| | - Caroline Kistorp
- Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
3
|
Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res 2023; 119:28-44. [PMID: 35388416 DOI: 10.1093/cvr/cvac027] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 12/07/2021] [Accepted: 12/28/2021] [Indexed: 11/12/2022] Open
Abstract
Aldosterone's role in the kidney and its pathophysiologic actions in hypertension are well known. However, its role or that of its receptor [minieralocorticoid receptor (MR)] in other cardiovascular (CV) disease are less well described. To identify their potential roles in six CV conditions (heart failure, myocardial infarction, atrial fibrillation, stroke, atherosclerosis, and thrombosis), we assessed these associations in the following four areas: (i) mechanistic studies in rodents and humans; (ii) pre-clinical studies of MR antagonists; (iii) clinical trials of MR antagonists; and (iv) genetics. The data were acquired from an online search of the National Library of Medicine using the PubMed search engine from January 2011 through June 2021. There were 3702 publications identified with 200 publications meeting our inclusion and exclusion criteria. Data strongly supported an association between heart failure and dysregulated aldosterone/MR. This association is not surprising given aldosterone/MR's prominent role in regulating sodium/volume homeostasis. Atrial fibrillation and myocardial infarction are also associated with dysregulated aldosterone/MR, but less strongly. For the most part, the data were insufficient to determine whether there was a relationship between atherosclerosis, stroke, or thrombosis and aldosterone/MR dysregulation. This review clearly documented an expanding role for aldosterone/MR's dysregulation in CV diseases beyond hypertension. How expansive it might be is limited by the currently available data. It is anticipated that with an increased focus on aldosterone/MR's potential roles in these diseases, additional clinical and pre-clinical data will clarify these relationships, thereby, opening approaches to use modulators of aldosterone/MR's action to more precisely treat these CV conditions.
Collapse
Affiliation(s)
- Wasita W Parksook
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- Division of Endocrinology and Metabolism, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
- Division of General Internal Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
| | - Gordon H Williams
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
4
|
Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. Int J Mol Sci 2023; 24:ijms24031922. [PMID: 36768246 PMCID: PMC9915890 DOI: 10.3390/ijms24031922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/14/2023] [Accepted: 01/16/2023] [Indexed: 01/20/2023] Open
Abstract
Inappropriate mineralocorticoid receptor (MR) activation in different cardiovascular cell types has deleterious effects on cardiac remodeling and function. Therefore, MR inhibition is a crucial pharmacological strategy to overcome cardiovascular dysfunction. Despite efficient blockade of MR with steroidal MR antagonists (MRAs), their clinical application is unsatisfactory due to the adverse effects. Newer non-steroidal MRAs with greater potency could be suitable for clinical application, especially in patients with type 2 diabetes mellitus and chronic kidney disease. Although clinical evidence has shown the beneficial effects of non-steroidal MRAs on cardiovascular outcomes in patients with heart failure with reduced ejection fraction, clinical trials are ongoing to evaluate the efficacy of heart failure with preserved ejection fraction. Therefore, comparative pharmacological characterization of non-steroidal MRAs over classic steroidal MRAs is crucial. Here, we summarize the pre-clinical evidence of non-steroidal MRAs, which suggests an improvement in cardiac dysfunction, as well as the underlying molecular mechanisms in animal models mimicking different clinical conditions. In addition, we discuss up-to-date information from clinical trials regarding the beneficial effects of non-steroidal MRAs on meaningful cardiovascular outcomes. Both pre-clinical and clinical evidence support treatment with non-steroidal MRAs in patients with cardiovascular disease.
Collapse
|
5
|
Ahmadi-Noorbakhsh S, Farajli Abbasi M, Ghasemi M, Bayat G, Davoodian N, Sharif-Paghaleh E, Poormoosavi SM, Rafizadeh M, Maleki M, Shirzad-Aski H, Kargar Jahromi H, Dadkhah M, Khalvati B, Safari T, Behmanesh MA, Khoshnam SE, Houshmand G, Talaei SA. Anesthesia and analgesia for common research models of adult mice. Lab Anim Res 2022; 38:40. [PMID: 36514128 PMCID: PMC9746144 DOI: 10.1186/s42826-022-00150-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 11/23/2022] [Accepted: 12/06/2022] [Indexed: 12/15/2022] Open
Abstract
Anesthesia and analgesia are major components of many interventional studies on laboratory animals. However, various studies have shown improper reporting or use of anesthetics/analgesics in research proposals and published articles. In many cases, it seems "anesthesia" and "analgesia" are used interchangeably, while they are referring to two different concepts. Not only this is an unethical practice, but also it may be one of the reasons for the proven suboptimal quality of many animal researches. This is a widespread problem among investigations on various species of animals. However, it could be imagined that it may be more prevalent for the most common species of laboratory animals, such as the laboratory mice. In this review, proper anesthetic/analgesic methods for routine procedures on laboratory mice are discussed. We considered the available literature and critically reviewed their anesthetic/analgesic methods. Detailed dosing and pharmacological information for the relevant drugs are provided and some of the drugs' side effects are discussed. This paper provides the necessary data for an informed choice of anesthetic/analgesic methods in some routine procedures on laboratory mice.
Collapse
Affiliation(s)
- Siavash Ahmadi-Noorbakhsh
- grid.411705.60000 0001 0166 0922Preclinical Core Facility (TPCF), Tehran University of Medical Sciences, Tehran, Iran ,grid.415814.d0000 0004 0612 272XThe National Ethics Committee for Biomedical Research, Floor 13th, Complex A, Ministry of Health and Medical Education, Eyvanak Blvd., Shahrake Gharb, Tehran, Iran
| | - Mohammad Farajli Abbasi
- grid.412105.30000 0001 2092 9755Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Maedeh Ghasemi
- grid.411036.10000 0001 1498 685XDepartment of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Gholamreza Bayat
- grid.411705.60000 0001 0166 0922Department of Physiology-Pharmacology-Medical Physic, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | - Nahid Davoodian
- grid.412237.10000 0004 0385 452XEndocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
| | - Ehsan Sharif-Paghaleh
- grid.411705.60000 0001 0166 0922Preclinical Core Facility (TPCF), Tehran University of Medical Sciences, Tehran, Iran ,grid.411705.60000 0001 0166 0922Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran ,grid.13097.3c0000 0001 2322 6764Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, England
| | - Seyedeh Mahsa Poormoosavi
- grid.512425.50000 0004 4660 6569Department of Histology, School of Medicine, Research and Clinical Center for Infertility, Dezful University of Medical Sciences, Dezful, Iran
| | - Melika Rafizadeh
- grid.411600.2Department of Pharmacology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Maryam Maleki
- grid.449129.30000 0004 0611 9408Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
| | - Hesamaddin Shirzad-Aski
- grid.411747.00000 0004 0418 0096Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - Hossein Kargar Jahromi
- grid.444764.10000 0004 0612 0898Research Center for Non-Communicable Disease, Jahrom University of Medical Sciences, Jahrom, Iran
| | - Masoomeh Dadkhah
- grid.411426.40000 0004 0611 7226Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Bahman Khalvati
- grid.413020.40000 0004 0384 8939Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
| | - Tahereh Safari
- grid.488433.00000 0004 0612 8339School of Medicine, Department of Physiology, PhD, Zahedan University of Medical Sciences, Zahedan, Iran ,grid.488433.00000 0004 0612 8339Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
| | - Mohammad Amin Behmanesh
- grid.512425.50000 0004 4660 6569Department of Histology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
| | - Seyed Esmaeil Khoshnam
- grid.411230.50000 0000 9296 6873Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Gholamreza Houshmand
- grid.411623.30000 0001 2227 0923Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Department of Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Sayyed Alireza Talaei
- grid.444768.d0000 0004 0612 1049Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
| |
Collapse
|
6
|
Paul B, Sterner ZR, Bhawal R, Anderson ET, Zhang S, Buchholz DR. Impaired negative feedback and death following acute stress in glucocorticoid receptor knockout Xenopus tropicalis tadpoles. Gen Comp Endocrinol 2022; 326:114072. [PMID: 35697317 DOI: 10.1016/j.ygcen.2022.114072] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 06/03/2022] [Accepted: 06/07/2022] [Indexed: 11/21/2022]
Abstract
Blood glucocorticoid levels are regulated by the hypothalamo-pituitary-adrenal/interrenal axis (HPA axis in mammals, HPI axis in amphibians), and negative feedback by glucocorticoid signaling is a key player in that regulation. Glucocorticoid and mineralocorticoid receptors (GR and MR) mediate negative feedback in mammals, but little is known about nuclear receptor-mediated feedback in amphibians. Because amphibians have only one corticosteroidogenic cell type responsible for glucocorticoid and mineralocorticoid production, we hypothesized that GR knockout (GRKO) tadpoles have elevated levels of glucocorticoids and mineralocorticoids as well as axis components regulating their production. We also examined the response to stress and potential for increased aldosterone signaling in GRKO tadpoles. We found that GRKO tadpoles have severe hyperactivity of the HPI axis, namely high mRNA expression levels of pomc, cyp17a1, cyp21a2, cyp11b2, and star, and high tissue content of corticosterone, aldosterone, 17-hydroxyprogesterone, 21-deoxycortisol, and progesterone. Such aberrant HPI activity was accompanied by reduced survival after acute temperature shock and shaking stress. Like mammalian models of HPA hyperactivity, GRKO tadpoles have high MR mRNA expression levels in brain, kidney, heart, and skin and high levels of the inflammatory cytokine tnf-α and the profibrotic factor tgf-β in kidneys. This study showed GR is critical for negative feedback to the amphibian HPI axis and for survival from acute stressors. This study also showed GRKO tadpoles exhibit altered expression/overproduction of regulators of salt-water homeostasis and associated biomarkers of kidney disease.
Collapse
Affiliation(s)
- Bidisha Paul
- Department of Biological Sciences, University of Cincinnati, Cincinnati, OH 45221, United States
| | - Zachary R Sterner
- Department of Biological Sciences, University of Cincinnati, Cincinnati, OH 45221, United States
| | - Ruchika Bhawal
- Proteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853, United States
| | - Elizabeth T Anderson
- Proteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853, United States
| | - Sheng Zhang
- Proteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853, United States
| | - Daniel R Buchholz
- Department of Biological Sciences, University of Cincinnati, Cincinnati, OH 45221, United States.
| |
Collapse
|
7
|
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci 2022; 23:ijms23169243. [PMID: 36012508 PMCID: PMC9408839 DOI: 10.3390/ijms23169243] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 08/11/2022] [Accepted: 08/12/2022] [Indexed: 11/17/2022] Open
Abstract
Perception of the role of the aldosterone/mineralocorticoid receptor (MR) ensemble has been extended from a previously renal epithelial-centered focus on sodium and volume homeostasis to an understanding of their role as systemic modulators of reactive oxygen species, inflammation, and fibrosis. Steroidal MR antagonists (MRAs) are included in treatment paradigms for resistant hypertension and heart failure with reduced ejection fraction, while more recently, the nonsteroidal MRA finerenone was shown to reduce renal and cardiovascular outcomes in two large phase III trials (FIDELIO-DKD and FIGARO-DKD) in patients with chronic kidney disease and type 2 diabetes, respectively. Here, we provide an overview of the pathophysiologic role of MR overactivation and preclinical evidence with the nonsteroidal MRA finerenone in a range of different disease models with respect to major components of the aggregate mode of action, including interfering with reactive oxygen species generation, inflammation, fibrosis, and hypertrophy. We describe a time-dependent effect of these mechanistic components and the potential modification of major clinical parameters, as well as the impact on clinical renal and cardiovascular outcomes as observed in FIDELIO-DKD and FIGARO-DKD. Finally, we provide an outlook on potential future clinical indications and ongoing clinical studies with finerenone, including a combination study with a sodium–glucose cotransporter-2 inhibitor.
Collapse
|
8
|
Howard ZM, Gomatam CK, Piepho AB, Rafael-Fortney JA. Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury. Front Pharmacol 2022; 13:942660. [PMID: 35837290 PMCID: PMC9273774 DOI: 10.3389/fphar.2022.942660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 06/10/2022] [Indexed: 11/13/2022] Open
Abstract
Duchenne muscular dystrophy (DMD) is a striated muscle degenerative disease due to loss of functional dystrophin protein. Loss of dystrophin results in susceptibility of muscle membranes to damage, leading to muscle degeneration and continuous inflammation and fibrosis that further exacerbate pathology. Long-term glucocorticoid receptor (GR) agonist treatment, the current standard-of-care for DMD, modestly improves prognosis but has serious side effects. The mineralocorticoid receptor (MR), a ligand-activated transcription factor present in many cell types, has been implicated as a therapeutic target for DMD. MR antagonists (MRAs) have fewer side effects than GR agonists and are used clinically for heart failure. MRA efficacy has recently been demonstrated for DMD cardiomyopathy and in preclinical studies, MRAs also alleviate dystrophic skeletal muscle pathology. MRAs lead to improvements in muscle force and membrane stability and reductions in degeneration, inflammation, and fibrosis in dystrophic muscles. Myofiber-specific MR knockout leads to most of these improvements, supporting an MR-dependent mechanism of action, but MRAs additionally stabilize myofiber membranes in an MR-independent manner. Immune cell MR signaling in dystrophic and acutely injured normal muscle contributes to wound healing, and myeloid-specific MR knockout is detrimental. More research is needed to fully elucidate MR signaling in striated muscle microenvironments. Direct comparisons of genomic and non-genomic effects of glucocorticoids and MRAs on skeletal muscles and heart will contribute to optimal temporal use of these drugs, since they compete for binding conserved receptors. Despite the advent of genetic medicines, therapies targeting inflammation and fibrosis will be necessary to achieve optimal patient outcomes.
Collapse
|
9
|
Liu T, Li YL, Zhou LJ, Sun XN, Wang YL, Du LJ, Liu Y, Zhu H, Chen BY, Sun JY, Liu Y, Xu S, Ye HL, Huang SJ, Wang X, Li B, Duan SZ. Mineralocorticoid Receptor Deficiency in Treg Cells Ameliorates DSS-Induced Colitis in a Gut Microbiota-Dependent Manner. Immunology 2022; 167:94-104. [PMID: 35751882 DOI: 10.1111/imm.13522] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 06/14/2022] [Indexed: 11/29/2022] Open
Abstract
Mineralocorticoid receptor (MR) is a classic nuclear receptor and an effective drug target in the cardiovascular system. The function of MR in immune cells such as macrophages and T cells has been increasingly appreciated. The aim of this study was to investigate the function of Treg MR in the process of inflammatory bowel disease (IBD). We treated Treg MR-deficient (MRflox/flox Foxp3YFP-Cre , KO) mice and control (Foxp3YFP-Cre , WT) mice with dextran sodium sulphate (DSS) to induce colitis and found that the severity of DSS-induced colitis was markedly alleviated in Treg MR-deficient mice, accompanied by reduced production of inflammatory cytokines, and relieved infiltration of monocytes, neutrophils and interferon γ+ T cells in colon lamina propria. Fecal microbiota of mice with colitis was analyzed by 16S rRNA gene sequencing and the composition of gut microbiota was vastly changed in Treg MR-deficient mice. Furthermore, depletion of gut microbiota by antibiotics abolished the protective effects of Treg MR deficiency and resulted in similar severity of DSS-induced colitis in WT and KO mice. Fecal microbiota transplantation from KO mice attenuated DSS-induced colitis characterized by alleviated inflammatory infiltration compared to that from WT mice. Hence, our study demonstrates that Treg MR deficiency protects against DSS-induced colitis by attenuation of colonic inflammatory infiltration. Gut microbiota is both sufficient and necessary for Treg MR deficiency to exert the beneficial effects.
Collapse
Affiliation(s)
- Ting Liu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Yu-Lin Li
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Lu-Jun Zhou
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Xue-Nan Sun
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Yong-Li Wang
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Lin-Juan Du
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Yuan Liu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Hong Zhu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Bo-Yan Chen
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Jian-Yong Sun
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Yan Liu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Shuo Xu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Hui-Lin Ye
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Shi-Jia Huang
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| | - Xiaoxia Wang
- Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Bin Li
- Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Sheng-Zhong Duan
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai, China
| |
Collapse
|
10
|
Hengel FE, Benitah JP, Wenzel UO. Mosaic theory revised: inflammation and salt play central roles in arterial hypertension. Cell Mol Immunol 2022; 19:561-576. [PMID: 35354938 PMCID: PMC9061754 DOI: 10.1038/s41423-022-00851-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 02/21/2022] [Indexed: 02/06/2023] Open
Abstract
The mosaic theory of hypertension was advocated by Irvine Page ~80 years ago and suggested that hypertension resulted from the close interactions of different causes. Increasing evidence indicates that hypertension and hypertensive end-organ damage are not only mediated by the proposed mechanisms that result in hemodynamic injury. Inflammation plays an important role in the pathophysiology and contributes to the deleterious consequences of arterial hypertension. Sodium intake is indispensable for normal body function but can be detrimental when it exceeds dietary requirements. Recent data show that sodium levels also modulate the function of monocytes/macrophages, dendritic cells, and different T-cell subsets. Some of these effects are mediated by changes in the microbiome and metabolome due to high-salt intake. The purpose of this review is to propose a revised and extended version of the mosaic theory by summarizing and integrating recent advances in salt, immunity, and hypertension research. Salt and inflammation are placed in the middle of the mosaic because both factors influence each of the remaining pieces.
Collapse
|
11
|
Howard ZM, Rastogi N, Lowe J, Hauck JS, Ingale P, Gomatam C, Gomez-Sanchez CE, Gomez-Sanchez EP, Bansal SS, Rafael-Fortney JA. Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury. Am J Physiol Cell Physiol 2022; 322:C354-C369. [PMID: 35044859 PMCID: PMC8858682 DOI: 10.1152/ajpcell.00411.2021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 01/13/2022] [Accepted: 01/13/2022] [Indexed: 11/22/2022]
Abstract
Suppressing mineralocorticoid receptor (MR) activity with MR antagonists is therapeutic for chronic skeletal muscle pathology in Duchenne muscular dystrophy (DMD) mouse models. Although mechanisms underlying clinical MR antagonist efficacy for DMD cardiomyopathy and other cardiac diseases are defined, mechanisms in skeletal muscles are not fully elucidated. Myofiber MR knockout improves skeletal muscle force and a subset of dystrophic pathology. However, MR signaling in myeloid cells is known to be a major contributor to cardiac efficacy. To define contributions of myeloid MR in skeletal muscle function and disease, we performed parallel assessments of muscle pathology, cytokine levels, and myeloid cell populations resulting from myeloid MR genetic knockout in muscular dystrophy and acute muscle injury. Myeloid MR knockout led to lower levels of C-C motif chemokine receptor 2 (CCR2)-expressing macrophages, resulting in sustained myofiber damage after acute injury of normal muscle. In acute injury, myeloid MR knockout also led to increased local muscle levels of the enzyme that produces the endogenous MR agonist aldosterone, further supporting important contributions of MR signaling in normal muscle repair. In muscular dystrophy, myeloid MR knockout altered cytokine levels differentially between quadriceps and diaphragm muscles, which contain different myeloid populations. Myeloid MR knockout led to higher levels of fibrosis in dystrophic diaphragm. These results support important contributions of myeloid MR signaling to skeletal muscle repair in acute and chronic injuries and highlight the useful information gained from cell-specific genetic knockouts to delineate mechanisms of pharmacological efficacy.
Collapse
MESH Headings
- Aldosterone/metabolism
- Animals
- Barium Compounds
- Chlorides
- Cytokines/genetics
- Cytokines/metabolism
- Diaphragm/immunology
- Diaphragm/metabolism
- Diaphragm/pathology
- Disease Models, Animal
- Female
- Fibrosis
- Macrophages/immunology
- Macrophages/metabolism
- Male
- Mice, Inbred mdx
- Mice, Knockout
- Muscular Diseases/chemically induced
- Muscular Diseases/immunology
- Muscular Diseases/metabolism
- Muscular Diseases/pathology
- Muscular Dystrophy, Duchenne/genetics
- Muscular Dystrophy, Duchenne/immunology
- Muscular Dystrophy, Duchenne/metabolism
- Muscular Dystrophy, Duchenne/pathology
- Quadriceps Muscle/immunology
- Quadriceps Muscle/metabolism
- Quadriceps Muscle/pathology
- Receptors, CCR2/genetics
- Receptors, CCR2/metabolism
- Receptors, Mineralocorticoid/genetics
- Receptors, Mineralocorticoid/metabolism
- Signal Transduction
- Mice
Collapse
Affiliation(s)
- Zachary M Howard
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Neha Rastogi
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Jeovanna Lowe
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - J Spencer Hauck
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Pratham Ingale
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Chetan Gomatam
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Celso E Gomez-Sanchez
- Jackson Department of Veterans Affairs Medical Center, Jackson, Mississippi
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Elise P Gomez-Sanchez
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Shyam S Bansal
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
- Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Jill A Rafael-Fortney
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio
| |
Collapse
|
12
|
Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol 2022; 84:585-610. [PMID: 35143332 DOI: 10.1146/annurev-physiol-060821-013950] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Mineralocorticoid receptor (MR) activation in the heart and vessels leads to pathological effects, such as excessive extracellular matrix accumulation, oxidative stress, and sustained inflammation. In these organs, the MR is expressed in cardiomyocytes, fibroblasts, endothelial cells, smooth muscle cells, and inflammatory cells. We review the accumulating experimental and clinical evidence that pharmacological MR antagonism has a positive impact on a battery of cardiac and vascular pathological states, including heart failure, myocardial infarction, arrhythmic diseases, atherosclerosis, vascular stiffness, and cardiac and vascular injury linked to metabolic comorbidities and chronic kidney disease. Moreover, we present perspectives on optimization of the use of MR antagonists in patients more likely to respond to such therapy and review the evidence suggesting that novel nonsteroidal MR antagonists offer an improved safety profile while retaining their cardiovascular protective effects. Finally, we highlight future therapeutic applications of MR antagonists in cardiovascular injury.
Collapse
Affiliation(s)
- Jonatan Barrera-Chimal
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.,Laboratorio de Fisiología Cardiovascular y Trasplante Renal, Unidad de Investigación UNAM-INC, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Benjamin Bonnard
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France;
| | - Frederic Jaisser
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France; .,INSERM Centre d'Investigations Cliniques-Plurithématique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN INI-CRCT), Université de Lorraine, Nancy, France
| |
Collapse
|
13
|
Carvajal CA, Tapia-Castillo A, Pérez JA, Fardella CE. Primary Aldosteronism, Aldosterone, and Extracellular Vesicles. Endocrinology 2022; 163:6433012. [PMID: 34918071 DOI: 10.1210/endocr/bqab240] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Indexed: 01/02/2023]
Abstract
Primary aldosteronism (PA) is an endocrine related condition leading to arterial hypertension due to inappropriately high and unregulated aldosterone concentration. Recently, a broad spectrum of PA has been recognized, which brings new challenges associated with early identification of this condition that affect renal epithelial and extrarenal tissues. Reports have shown the potential role of extracellular vesicles (EVs) and EV cargo as novel and complementary biomarkers in diagnosis and prognosis of PA. In vivo and in vitro studies have identified specific EV surface antigens, EV-proteins, and EV microRNAs that can be useful to develop novel diagnostic algorithms to detect, confirm, or follow up the PA. Moreover, the study of EVs in the field of PA provides further insight in the pathophysiological mechanism of the PA disease.
Collapse
Affiliation(s)
- Cristian A Carvajal
- Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
- Millennium Institute of Immunology and Immunotherapy (IMII-ICM), Santiago, Chile
- Centro Traslacional de Endocrinología UC (CETREN-UC), Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Alejandra Tapia-Castillo
- Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
- Millennium Institute of Immunology and Immunotherapy (IMII-ICM), Santiago, Chile
- Centro Traslacional de Endocrinología UC (CETREN-UC), Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Jorge A Pérez
- Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
- Millennium Institute of Immunology and Immunotherapy (IMII-ICM), Santiago, Chile
- Centro Traslacional de Endocrinología UC (CETREN-UC), Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Carlos E Fardella
- Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
- Millennium Institute of Immunology and Immunotherapy (IMII-ICM), Santiago, Chile
- Centro Traslacional de Endocrinología UC (CETREN-UC), Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|
14
|
Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol 2022; 18:56-70. [PMID: 34675379 DOI: 10.1038/s41581-021-00490-8] [Citation(s) in RCA: 84] [Impact Index Per Article: 42.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/13/2021] [Indexed: 01/19/2023]
Abstract
Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and current therapies that limit CKD progression and the development of cardiovascular disease (CVD) include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and sodium-glucose co-transporter 2 (SGLT2) inhibitors. Despite the introduction of these therapeutics, an important residual risk of CKD progression and cardiovascular death remains in patients with T2D. Mineralocorticoid receptor antagonists (MRAs) are a promising therapeutic option in diabetic kidney disease (DKD) owing to the reported effects of mineralocorticoid receptor activation in inflammatory cells, podocytes, fibroblasts, mesangial cells and vascular cells. In preclinical studies, MRAs consistently reduce albuminuria, CKD progression, and activation of fibrotic and inflammatory pathways. DKD clinical studies have similarly demonstrated that steroidal MRAs lead to albuminuria reduction compared with placebo, although hyperkalaemia is a major secondary effect. Non-steroidal MRAs carry a lower risk of hyperkalaemia than steroidal MRAs, and the large FIDELIO-DKD clinical trial showed that the non-steroidal MRA finerenone also slowed CKD progression and reduced the risk of adverse cardiovascular outcomes compared with placebo in patients with T2D. Encouragingly, other non-steroidal MRAs have anti-albuminuric properties in DKD. Whether or not combining MRAs with other renoprotective drugs such as SGLT2 inhibitors might provide additive protective effects warrants further investigation.
Collapse
Affiliation(s)
- Jonatan Barrera-Chimal
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, Mexico City, Mexico.,Laboratorio de Fisiología Cardiovascular y Trasplante Renal, Unidad de Investigación UNAM-INC, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Ixchel Lima-Posada
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France
| | - George L Bakris
- American Heart Association Comprehensive Hypertension Centre, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA
| | - Frederic Jaisser
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France. .,Université de Lorraine, INSERM Centre d'Investigations Cliniques-Plurithématique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT, Nancy, France.
| |
Collapse
|
15
|
van der Heijden CDCC, Bode M, Riksen NP, Wenzel UO. The role of the mineralocorticoid receptor in immune cells in in cardiovascular disease. Br J Pharmacol 2021; 179:3135-3151. [PMID: 34935128 DOI: 10.1111/bph.15782] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 10/22/2021] [Accepted: 11/22/2021] [Indexed: 11/29/2022] Open
Abstract
Chronic low-grade inflammation and immune cell activation are important mechanisms in the pathophysiology of cardiovascular disease (CVD). Therefore, targeted immunosuppression is a promising novel therapy to lower cardiovascular risk. In this review, we identify the mineralocorticoid receptor (MR) on immune cells as a potential target to modulate inflammation. The MR is present in almost all cells of the cardiovascular system, including immune cells. Activation of the MR in innate and adaptive immune cells induces inflammation which can contribute to CVD, by inducing endothelial dysfunction and hypertension. Moreover, it accelerates atherosclerotic plaque formation and destabilization and impairs tissue regeneration after ischemic events. Identifying the molecular targets for these non-renal actions of the MR provide promising novel cardiovascular drug targets for mineralocorticoid receptor antagonists (MRAs), which are currently mainly applied in hypertension and heart failure.
Collapse
Affiliation(s)
| | - Marlies Bode
- III. Department of Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Niels P Riksen
- Department of Internal Medicine, Radboud University Medical Center, GA, Nijmegen, The Netherlands.,Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, GA, The Netherlands
| | - Ulrich O Wenzel
- III. Department of Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
16
|
Kowalski J, Deng L, Suennen C, Koca D, Meral D, Bode C, Hein L, Lother A. Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells. Hypertension 2021; 78:456-465. [PMID: 33966455 DOI: 10.1161/hypertensionaha.120.16196] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Jessica Kowalski
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany
| | - Lisa Deng
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany
| | - Chiara Suennen
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany
| | - Duygu Koca
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany
| | - David Meral
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany.,Spemann Graduate School of Biology and Medicine (SGBM), Cardiovascular Research Track (D.M.), University of Freiburg, Germany
| | - Christoph Bode
- Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center Freiburg University (C.B., A.L.), University of Freiburg, Germany
| | - Lutz Hein
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany.,BIOSS Centre for Biological Signaling Studies (L.H.), University of Freiburg, Germany
| | - Achim Lother
- From the Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine (J.K., L.D., C.S., D.K., D.M., L.H., A.L.), University of Freiburg, Germany.,Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center Freiburg University (C.B., A.L.), University of Freiburg, Germany
| |
Collapse
|
17
|
Manrique-Acevedo C, Padilla J, Naz H, Woodford ML, Ghiarone T, Aroor AR, Hulse JL, Cabral-Amador FJ, Martinez-Diaz V, Hans CP, Whaley-Connell A, Martinez-Lemus LA, Lastra G. Mineralocorticoid Receptor in Myeloid Cells Mediates Angiotensin II-Induced Vascular Dysfunction in Female Mice. Front Physiol 2021; 12:588358. [PMID: 33854438 PMCID: PMC8039313 DOI: 10.3389/fphys.2021.588358] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Accepted: 02/17/2021] [Indexed: 11/13/2022] Open
Abstract
Enhanced mineralocorticoid receptor (MR) signaling is critical to the development of endothelial dysfunction and arterial stiffening. However, there is a lack of knowledge about the role of MR-induced adipose tissue inflammation in the genesis of vascular dysfunction in women. In this study, we hypothesize that MR activation in myeloid cells contributes to angiotensin II (Ang II)-induced aortic stiffening and endothelial dysfunction in females via increased pro-inflammatory (M1) macrophage polarization. Female mice lacking MR in myeloid cells (MyMRKO) were infused with Ang II (500 ng/kg/min) for 4 weeks. This was followed by determinations of aortic stiffness and vasomotor responses, as well as measurements of markers of inflammation and macrophage infiltration/polarization in different adipose tissue compartments. MyMRKO mice were protected against Ang II-induced aortic endothelial stiffening, as assessed via atomic force microscopy in aortic explants, and vasorelaxation dysfunction, as measured by aortic wire myography. In alignment, MyMRKO mice were protected against Ang II-induced macrophage infiltration and M1 polarization in visceral adipose tissue (VAT) and thoracic perivascular adipose tissue (tPVAT). Collectively, this study demonstrates a critical role of MR activation in myeloid cells in the pathogenesis of vascular dysfunction in females associated with pro-inflammatory macrophage polarization in VAT and tPVAT. Our data have potential clinical implications for the prevention and management of cardiovascular disease in women, who are disproportionally at higher risk for poor outcomes.
Collapse
Affiliation(s)
- Camila Manrique-Acevedo
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States.,Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States.,Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States
| | - Jaume Padilla
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States.,Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States
| | - Huma Naz
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States.,Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States
| | - Makenzie L Woodford
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States.,Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States
| | - Thaysa Ghiarone
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States
| | - Annayya R Aroor
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States.,Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States
| | - Jack L Hulse
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States
| | | | - Vanesa Martinez-Diaz
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States
| | - Chetan P Hans
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States.,Division of Cardiovascular Medicine, Department of Medicine, University of Missouri, Columbia, MO, United States
| | - Adam Whaley-Connell
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States.,Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States.,Division of Nephrology and Hypertension, Department of Medicine, University of Missouri, Columbia, MO, United States
| | - Luis A Martinez-Lemus
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States.,Department of Biomedical, Biological and Chemical Engineering, University of Missouri, Columbia, MO, United States.,Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, United States
| | - Guido Lastra
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, MO, United States.,Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States
| |
Collapse
|
18
|
Kim SK, Biwer LA, Moss ME, Man JJ, Aronovitz MJ, Martin GL, Carrillo-Salinas FJ, Salvador AM, Alcaide P, Jaffe IZ. Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload-Induced Heart Failure. Circ Heart Fail 2021; 14:e007279. [PMID: 33517669 DOI: 10.1161/circheartfailure.120.007279] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Mineralocorticoid receptor (MR) antagonists decrease heart failure (HF) hospitalization and mortality, but the mechanisms are unknown. Preclinical studies reveal that the benefits on cardiac remodeling and dysfunction are not completely explained by inhibition of MR in cardiomyocytes, fibroblasts, or endothelial cells. The role of MR in smooth muscle cells (SMCs) in HF has never been explored. METHODS Male mice with inducible deletion of MR from SMCs (SMC-MR-knockout) and their MR-intact littermates were exposed to HF induced by 27-gauge transverse aortic constriction versus sham surgery. HF phenotypes and mechanisms were measured 4 weeks later using cardiac ultrasound, intracardiac pressure measurements, exercise testing, histology, cardiac gene expression, and leukocyte flow cytometry. RESULTS Deletion of MR from SMC attenuated transverse aortic constriction-induced HF with statistically significant improvements in ejection fraction, cardiac stiffness, chamber dimensions, intracardiac pressure, pulmonary edema, and exercise capacity. Mechanistically, SMC-MR-knockout protected from adverse cardiac remodeling as evidenced by decreased cardiomyocyte hypertrophy and fetal gene expression, interstitial and perivascular fibrosis, and inflammatory and fibrotic gene expression. Exposure to pressure overload resulted in a statistically significant decline in cardiac capillary density and coronary flow reserve in MR-intact mice. These vascular parameters were improved in SMC-MR-knockout mice compared with MR-intact littermates exposed to transverse aortic constriction. CONCLUSIONS These results provide a novel paradigm by which MR inhibition may be beneficial in HF by blocking MR in SMC, thereby improving cardiac blood supply in the setting of pressure overload-induced hypertrophy, which in turn mitigates the adverse cardiac remodeling that contributes to HF progression and symptoms.
Collapse
Affiliation(s)
- Seung Kyum Kim
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.).,Department of Sports Science, Seoul National University of Science and Technology, Republic of Korea, Seoul, South Korea (S.K.K.)
| | - Lauren A Biwer
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.)
| | - M Elizabeth Moss
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.).,Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (M.E.M., J.J.M.)
| | - Joshua J Man
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.).,Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (M.E.M., J.J.M.)
| | - Mark J Aronovitz
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.)
| | - Gregory L Martin
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.)
| | | | - Ane M Salvador
- Department of Immunology, Tufts University School of Medicine, Boston, MA (F.J.C.-S., A.M.S., P.A.)
| | - Pilar Alcaide
- Department of Immunology, Tufts University School of Medicine, Boston, MA (F.J.C.-S., A.M.S., P.A.)
| | - Iris Z Jaffe
- Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (S.K.K., L.A.B., M.E.M., J.J.M., M.J.A., G.L.M., I.Z.J.)
| |
Collapse
|
19
|
Barrera‐Chimal J, Jaisser F. Vascular and inflammatory mineralocorticoid receptors in kidney disease. Acta Physiol (Oxf) 2020; 228:e13390. [PMID: 31529757 DOI: 10.1111/apha.13390] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 08/28/2019] [Accepted: 09/12/2019] [Indexed: 12/25/2022]
Abstract
Mineralocorticoid receptor (MR) activation in the kidney can occur outside the aldosterone-sensitive distal nephron in sites including the endothelium, smooth muscle and inflammatory cells. MR activation in these cells has deleterious effects on kidney structure and function by promoting oxidative injury, endothelial dysfunction and stiffness, vascular remodelling and calcification, decreased relaxation and activation of T cells and pro-inflammatory macrophages. Here, we review the data showing the cellular consequences of MR activation in endothelial, smooth muscle and inflammatory cells and how this affects the kidney in pathological situations. The evidence demonstrating a benefit of pharmacological or genetic MR inhibition in various models of kidney disease is also discussed.
Collapse
Affiliation(s)
- Jonatan Barrera‐Chimal
- Laboratorio de Fisiología Cardiovascular y Trasplante Renal Unidad de Investigación en Medicina Traslacional Universidad Nacional Autónoma de México and Instituto Nacional de Cardiología Ignacio Chávez Instituto de Investigaciones Biomédicas Mexico City Mexico
| | - Frederic Jaisser
- INSERM U1116 Clinical Investigation Centre Lorraine University Vandoeuvre‐lès‐Nancy France
- INI‐CRCT (Cardiovascular and Renal Clinical Trialists) F‐CRIN Network Nancy France
- INSERM UMRS 1138 Centre de Recherche des Cordeliers Sorbonne University Paris Descartes University Paris France
| |
Collapse
|
20
|
Li C, Sun XN, Chen BY, Zeng MR, Du LJ, Liu T, Gu HH, Liu Y, Li YL, Zhou LJ, Zheng XJ, Zhang YY, Zhang WC, Liu Y, Shi C, Shao S, Shi XR, Yi Y, Liu X, Wang J, Auwerx J, Wang ZV, Jia F, Li RG, Duan SZ. Nuclear receptor corepressor 1 represses cardiac hypertrophy. EMBO Mol Med 2019; 11:e9127. [PMID: 31532577 PMCID: PMC6835202 DOI: 10.15252/emmm.201809127] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 08/24/2019] [Accepted: 08/27/2019] [Indexed: 01/24/2023] Open
Abstract
The function of nuclear receptor corepressor 1 (NCoR1) in cardiomyocytes is unclear, and its physiological and pathological implications are unknown. Here, we found that cardiomyocyte‐specific NCoR1 knockout (CMNKO) mice manifested cardiac hypertrophy at baseline and had more severe cardiac hypertrophy and dysfunction after pressure overload. Knockdown of NCoR1 exacerbated whereas overexpression mitigated phenylephrine‐induced cardiomyocyte hypertrophy. Mechanistic studies revealed that myocyte enhancer factor 2a (MEF2a) and MEF2d mediated the effects of NCoR1 on cardiomyocyte hypertrophy. The receptor interaction domains (RIDs) of NCoR1 interacted with MEF2a to repress its transcriptional activity. Furthermore, NCoR1 formed a complex with MEF2a and class IIa histone deacetylases (HDACs) to suppress hypertrophy‐related genes. Finally, overexpression of RIDs of NCoR1 in the heart attenuated cardiac hypertrophy and dysfunction induced by pressure overload. In conclusion, NCoR1 cooperates with MEF2 and HDACs to repress cardiac hypertrophy. Targeting NCoR1 and the MEF2/HDACs complex may be an attractive therapeutic strategy to tackle pathological cardiac hypertrophy.
Collapse
Affiliation(s)
- Chao Li
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Xue-Nan Sun
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Bo-Yan Chen
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Meng-Ru Zeng
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Lin-Juan Du
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Ting Liu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Hui-Hui Gu
- Shanghai Jing'an District Central Hospital, Fudan University, Shanghai, China
| | - Yuan Liu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Yu-Lin Li
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Lu-Jun Zhou
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Xiao-Jun Zheng
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Yu-Yao Zhang
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.,Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Wu-Chang Zhang
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Yan Liu
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Chaoji Shi
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| | - Shuai Shao
- Department of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xue-Rui Shi
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Yi Yi
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Xu Liu
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Jun Wang
- Shanghai Jing'an District Central Hospital, Fudan University, Shanghai, China
| | - Johan Auwerx
- Laboratory of Integrative and Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Zhao V Wang
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Feng Jia
- Department of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ruo-Gu Li
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Sheng-Zhong Duan
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China
| |
Collapse
|
21
|
Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019; 96:302-319. [PMID: 31133455 DOI: 10.1016/j.kint.2019.02.030] [Citation(s) in RCA: 118] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 02/04/2019] [Accepted: 02/20/2019] [Indexed: 12/13/2022]
Abstract
Chronic kidney disease (CKD) represents a global health concern, and its prevalence is increasing. The ultimate therapeutic option for CKD is kidney transplantation. However, the use of drugs that target specific pathways to delay or halt CKD progression, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors is limited in clinical practice. Mineralocorticoid receptor activation in nonclassical tissues, such as the endothelium, smooth muscle cells, inflammatory cells, podocytes, and fibroblasts may have deleterious effects on kidney structure and function. Several preclinical studies have shown that mineralocorticoid receptor antagonists (MRAs) ameliorate or cure kidney injury and dysfunction in different models of kidney disease. In this review, we present the preclinical evidence showing a benefit of MRAs in acute kidney injury, the transition from acute kidney injury to CKD, hypertensive and diabetic nephropathy, glomerulonephritis, and kidney toxicity induced by calcineurin inhibitors. We also discuss the molecular mechanisms responsible for renoprotection related to MRAs that lead to reduced oxidative stress, inflammation, fibrosis, and hemodynamic alterations. The available clinical data support a benefit of MRA in reducing proteinuria in diabetic kidney disease and improving cardiovascular outcomes in CKD patients. Moreover, a benefit of MRAs in kidney transplantation has also been observed. The past and present clinical trials describing the effect of MRAs on kidney injury are presented, and the risk of hyperkalemia and use of other options, such as potassium binding agents or nonsteroidal MRAs, are also addressed. Altogether, the available preclinical and clinical data support a benefit of using MRAs in CKD, an approach that should be further explored in future clinical trials.
Collapse
Affiliation(s)
- Jonatan Barrera-Chimal
- Laboratorio de Fisiología Cardiovascular y Trasplante Renal, Unidad de Medicina Traslacional, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México and Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Sophie Girerd
- Transplant Unit, Nephrology Department, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France; Institut national de la santé et de la recherche médicale U1116, Clinical Investigation Centre, Lorraine University, Vandoeuvre-lès-Nancy, France; Investigation Network Initiative - Cardiovascular and Renal Clinical Trialists, French-Clinical Research Infrastructure Network, Nancy, France
| | - Frederic Jaisser
- Institut national de la santé et de la recherche médicale U1116, Clinical Investigation Centre, Lorraine University, Vandoeuvre-lès-Nancy, France; Investigation Network Initiative - Cardiovascular and Renal Clinical Trialists, French-Clinical Research Infrastructure Network, Nancy, France; Institut national de la santé et de la recherche médicale, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Sorbonne University, Paris Descartes University, Paris, France.
| |
Collapse
|
22
|
Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid Receptor and Cardiovascular Disease. Am J Hypertens 2018; 31:1165-1174. [PMID: 30192914 DOI: 10.1093/ajh/hpy120] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Accepted: 08/09/2018] [Indexed: 12/14/2022] Open
Abstract
Activation of the mineralocorticoid receptor (MR) in the distal nephron by its ligand, aldosterone, plays an important role in sodium reabsorption and blood pressure regulation. However, expression of the MR goes beyond the kidney. It is expressed in a variety of other tissues in which its activation could lead to tissue injury. Indeed, MR activation in the cardiovascular (CV) system has been shown to promote hypertension, fibrosis, and inflammation. Pharmacological blockade of the MR has protective effects in several animal models of CV disease. Furthermore, the use of MR antagonists is beneficial for heart failure patients, preventing mortality and morbidity. A better understanding of the implications of the MR in the setting of CV diseases is critical for refining treatments and improving patient care. The mechanisms involved in the deleterious effects of MR activation are complex and include oxidative stress, inflammation, and fibrosis. This review will discuss the pathological role of the MR in the CV system and the major mechanisms underlying it.
Collapse
Affiliation(s)
- Mathieu Buonafine
- INSERM, UMRS, Centre de Recherche des Cordeliers, Sorbonne University, Paris, France
- Paris Descartes University, Paris, France
| | - Benjamin Bonnard
- INSERM, UMRS, Centre de Recherche des Cordeliers, Sorbonne University, Paris, France
- Paris Descartes University, Paris, France
| | - Frédéric Jaisser
- INSERM, UMRS, Centre de Recherche des Cordeliers, Sorbonne University, Paris, France
- Paris Descartes University, Paris, France
- INSERM, Clinical Investigation Centre, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT, RHU Fight-HF, Nancy, France
| |
Collapse
|
23
|
Gomez I, Duval V, Silvestre JS. Cardiomyocytes and Macrophages Discourse on the Method to Govern Cardiac Repair. Front Cardiovasc Med 2018; 5:134. [PMID: 30333983 PMCID: PMC6175999 DOI: 10.3389/fcvm.2018.00134] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 09/05/2018] [Indexed: 12/11/2022] Open
Abstract
In response to pathophysiological stress, the cardiac tissue undergoes profound remodeling process that incorporates the elimination of dying resident cells, compensatory hypertrophy of functional cardiomyocytes, growth and remodeling of the vascular compartment and formation of a fibrotic scar. Accumulating evidences indicate that cardiac remodeling is, at least in part, controlled by a complex crosstalk between cardiomyocytes and macrophages. The strategic location of abundant macrophages to the proximity of cardiomyocytes suggest that they could regulate the fate of cardiomyocytes in the injured heart. As such, macrophages appear as critical support cells for cardiomyocytes and play central roles in cardiac hypertrophy, fibrosis and remodeling. Notably, the cardiac tissue expands heterogeneous population of cardiac macrophages through local proliferation of resident macrophage as well as recruitment and differentiation of blood-derived monocytes. It has also been suggested that cardiac-resident macrophages display distinct functional properties from that of monocyte-derived macrophages in cardiac tissue. Furthermore, macrophages are an overflowing source of biological entities with non-canonical roles on cardiac conduction or cardiomyocyte proliferation by regulating action potential diffusion or cardiac cell cycle reentry. Alternatively, stressed cardiomyocytes can trigger the release of a broad repertoire of instructive signals that can regulate macrophage number, skew their phenotype and therefore direct their beneficial or deleterious actions. In this review, we highlight recent discoveries describing how the intricate dialogue between cardiomyocytes and macrophages can shape the deleterious or healing signaling mechanisms in the injured cardiac tissue.
Collapse
Affiliation(s)
- Ingrid Gomez
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-970, Paris Centre de Recherche Cardiovasculaire, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Vincent Duval
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-970, Paris Centre de Recherche Cardiovasculaire, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jean-Sébastien Silvestre
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-970, Paris Centre de Recherche Cardiovasculaire, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
24
|
Patel B, Bansal SS, Ismahil MA, Hamid T, Rokosh G, Mack M, Prabhu SD. CCR2 + Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload. ACTA ACUST UNITED AC 2018; 3:230-244. [PMID: 30062209 PMCID: PMC6059350 DOI: 10.1016/j.jacbts.2017.12.006] [Citation(s) in RCA: 169] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 10/11/2017] [Accepted: 12/19/2017] [Indexed: 12/24/2022]
Abstract
Hypothesis: CCR2+ monocyte-derived cardiac macrophages are required for adverse LV remodeling, cardiac T-cell expansion, and the transition to HF following pressure overload. The imposition of pressure overload via TAC resulted in the early up-regulation of CCL2, CCL7, and CCL12 chemokines in the LV, increased Ly6ChiCCR2+ monocytes in the blood, and augmented CCR2+ infiltrating macrophages in the heart. Specific and circumscribed inhibition of CCR2+ monocytes and macrophages early during pressure overload reduced pathological hypertrophy, fibrosis, and systolic dysfunction during the late phase of pressure overload. The early expansion of CCR2+ macrophages after pressure overload was required for long-term cardiac T-cell expansion. CCR2+ monocytes/macrophages may represent key targets for immunomodulation to delay or prevent HF in pressure-overload states.
Although chronic inflammation is a central feature of heart failure (HF), the immune cell profiles differ with different underlying causes. This suggests that for immunomodulatory therapy in HF to be successful, it needs to be tailored to the specific etiology. Here, the authors demonstrate that monocyte-derived C-C chemokine receptor 2 (CCR2)+ macrophages infiltrate the heart early during pressure overload in mice, and that blocking this response either pharmacologically or with antibody-mediated CCR2+ monocyte depletion alleviates late pathological left ventricular remodeling and dysfunction, T-cell expansion, and cardiac fibrosis. Hence, suppression of CCR2+ monocytes/macrophages may be an important immunomodulatory therapeutic target to ameliorate pressure-overload HF.
Collapse
Key Words
- APC, antigen presenting cell
- BNP, B-type natriuretic peptide
- CCL, C-C motif chemokine ligand
- CCR2, C-C chemokine receptor 2
- DC, dendritic cell
- EDTA, ethylenediaminetetraacetic acid
- EF, ejection fraction
- HF, heart failure
- ICAM, intercellular adhesion molecule
- IFN, interferon
- IL, interleukin
- LN, lymph node
- LV, left ventricular
- MerTK, c-mer proto-oncogene tyrosine kinase
- PBS, phosphate-buffered saline
- T cells
- TAC, transverse aortic constriction
- TGF, transforming growth factor
- TNF, tumor necrosis factor
- VCAM, vascular cell adhesion molecule
- cardiac remodeling
- heart failure
- i.p., intraperitoneally
- inflammation
- macrophages
Collapse
Affiliation(s)
- Bindiya Patel
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Shyam S Bansal
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Mohamed Ameen Ismahil
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Tariq Hamid
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Gregg Rokosh
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Matthias Mack
- Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany
| | - Sumanth D Prabhu
- Department of Medicine, Division of Cardiovascular Disease and Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, Alabama.,Medical Service, Birmingham VAMC, Birmingham, Alabama
| |
Collapse
|
25
|
Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature. Am J Nephrol 2017; 46:298-314. [PMID: 29017166 PMCID: PMC6863172 DOI: 10.1159/000480652] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
BACKGROUND The remarkable success of clinical trials in mineralocorticoid receptor (MR) inhibition in heart failure has driven research on the physiological and pathological role(s) of nonepithelial MR expression. MR is widely expressed in the cardiovascular system and is a major determinant of endothelial function, smooth muscle tone, vascular remodeling, fibrosis, and blood pressure. An important new dimension is the appreciation of the role MR plays in immune cells and target organ damage in the heart, kidney and vasculature, and in the development of insulin resistance. SUMMARY The mechanism for MR activation in tissue injury continues to evolve with the evidence to date suggesting that activation of MR results in a complex repertoire of effects involving both macrophages and T cells. MR is an important transcriptional regulator of macrophage phenotype and function. Another important feature of MR activation is that it can occur even with normal or low aldosterone levels in pathological conditions. Tissue-specific conditional models of MR expression in myeloid cells, endothelial cells, smooth muscle cells and cardiomyocytes have been very informative and have firmly demonstrated a critical role of MR as a key pathophysiologic variable in cardiac hypertrophy, transition to heart failure, adipose inflammation, and atherosclerosis. Finally, the central nervous system activation of MR in permeable regions of the blood-brain barrier may play a role in peripheral inflammation. Key Message: Ongoing clinical trials will help clarify the role of MR blockade in conditions, such as atherosclerosis and chronic kidney disease.
Collapse
Affiliation(s)
- Zachary Belden
- Case Cardiovascular Research Institute, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - Jeffrey A. Deiuliis
- Case Cardiovascular Research Institute, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - Mirela Dobre
- Division of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - Sanjay Rajagopalan
- Case Cardiovascular Research Institute, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
- Harrington Heart and Vascular Institute, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
| |
Collapse
|
26
|
Li C, Sun XN, Zeng MR, Zheng XJ, Zhang YY, Wan Q, Zhang WC, Shi C, Du LJ, Ai TJ, Liu Y, Liu Y, Du LL, Yi Y, Yu Y, Duan SZ. Mineralocorticoid Receptor Deficiency in T Cells Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction Through Modulating T-Cell Activation. Hypertension 2017; 70:137-147. [PMID: 28559389 DOI: 10.1161/hypertensionaha.117.09070] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Revised: 01/25/2017] [Accepted: 04/28/2017] [Indexed: 12/11/2022]
Abstract
Although antagonists of mineralocorticoid receptor (MR) have been widely used to treat heart failure, the underlying mechanisms are incompletely understood. Recent reports show that T cells play important roles in pathologic cardiac hypertrophy and heart failure. However, it is unclear whether and how MR functions in T cells under these pathologic conditions. We found that MR antagonist suppressed abdominal aortic constriction-induced cardiac hypertrophy and decreased the accumulation and activation of CD4+ and CD8+ T cells in mouse heart. T-cell MR knockout mice manifested suppressed cardiac hypertrophy, fibrosis, and dysfunction compared with littermate control mice after abdominal aortic constriction. T-cell MR knockout mice had less cardiac inflammatory response, which was illustrated by decreased accumulation of myeloid cells and reduced expression of inflammatory cytokines. Less amounts and activation of T cells were observed in the heart of T-cell MR knockout mice after abdominal aortic constriction. In vitro studies showed that both MR antagonism and deficiency repressed activation of T cells, whereas MR overexpression elevated activation of T cells. These results demonstrated that MR blockade in T cells protected against abdominal aortic constriction-induced cardiac hypertrophy and dysfunction. Mechanistically, MR directly regulated T-cell activation and modulated cardiac inflammation. Targeting MR in T cells specifically may be a feasible strategy for more effective treatment of pathologic cardiac hypertrophy and heart failure.
Collapse
Affiliation(s)
- Chao Li
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Xue-Nan Sun
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Meng-Ru Zeng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Xiao-Jun Zheng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yu-Yao Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Qiangyou Wan
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Wu-Chang Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Chaoji Shi
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Lin-Juan Du
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Tang-Jun Ai
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yuan Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yan Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Li-Li Du
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Yi Yi
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Ying Yu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu)
| | - Sheng-Zhong Duan
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People's Hospital, School of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., L.-J.D., T.A, Yuan Liu, Yan Liu, S.-Z.D.), and Shanghai Key Laboratory of Stomatology (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., W.-C.Z., C.S., L.-J.D., T.-J.A., Yuan Liu, Yan Liu, S.-Z.D.), Shanghai Jiao Tong University School of Medicine, China; Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, China (C.L., X.-N.S., M.-R.Z., X.-J.Z., Y.-Y.Z., Q.W., L.-J.D., T.-J.A., Yuan Liu); Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, China (L.-L.D., Y. Yi); and Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, China (Y. Yu).
| |
Collapse
|
27
|
Sun XN, Li C, Liu Y, Du LJ, Zeng MR, Zheng XJ, Zhang WC, Liu Y, Zhu M, Kong D, Zhou L, Lu L, Shen ZX, Yi Y, Du L, Qin M, Liu X, Hua Z, Sun S, Yin H, Zhou B, Yu Y, Zhang Z, Duan SZ. T-Cell Mineralocorticoid Receptor Controls Blood Pressure by Regulating Interferon-Gamma. Circ Res 2017; 120:1584-1597. [DOI: 10.1161/circresaha.116.310480] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 03/07/2017] [Accepted: 03/13/2017] [Indexed: 11/16/2022]
Abstract
Rationale:
Hypertension remains to be a global public health burden and demands novel intervention strategies such as targeting T cells and T-cell–derived cytokines. Mineralocorticoid receptor (MR) antagonists have been clinically used to treat hypertension. However, the function of T-cell MR in blood pressure (BP) regulation has not been elucidated.
Objective:
We aim to determine the role of T-cell MR in BP regulation and to explore the mechanism.
Methods and Results:
Using T-cell MR knockout mouse in combination with angiotensin II–induced hypertensive mouse model, we demonstrated that MR deficiency in T cells strikingly decreased both systolic and diastolic BP and attenuated renal and vascular damage. Flow cytometric analysis showed that T-cell MR knockout mitigated angiotensin II–induced accumulation of interferon-gamma (IFN-γ)–producing T cells, particularly CD8
+
population, in both kidneys and aortas. Similarly, eplerenone attenuated angiotensin II–induced elevation of BP and accumulation of IFN-γ–producing T cells in wild-type mice. In cultured CD8
+
T cells, T-cell MR knockout suppressed IFN-γ expression whereas T-cell MR overexpression and aldosterone both enhanced IFN-γ expression. At the molecular level, MR interacted with NFAT1 (nuclear factor of activated T-cells 1) and activator protein-1 in T cells. Finally, T-cell MR overexpressing mice manifested more elevated BP compared with control mice after angiotensin II infusion and such difference was abolished by IFN-γ–neutralizing antibodies.
Conclusions:
MR may interact with NFAT1 and activator protein-1 to control IFN-γ in T cells and to regulate target organ damage and ultimately BP. Targeting MR in T cells specifically may be an effective novel approach for hypertension treatment.
Collapse
Affiliation(s)
- Xue-Nan Sun
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Chao Li
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Yuan Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Lin-Juan Du
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Meng-Ru Zeng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Xiao-Jun Zheng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Wu-Chang Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Yan Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Mingjiang Zhu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Deping Kong
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Li Zhou
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Limin Lu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Zhu-Xia Shen
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Yi Yi
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Lili Du
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Mu Qin
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Xu Liu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Zichun Hua
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Shuyang Sun
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Huiyong Yin
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Bin Zhou
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Ying Yu
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Zhiyuan Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| | - Sheng-Zhong Duan
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Ninth People’s Hospital, School of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.-Z.D.), Shanghai Key Laboratory of Stomatology (X.-N.S., C.L., Y.L., L.-J.D., M.-R.Z., X.-J.Z., W.-C.Z., Y.L., S.S., Z.Z., S.-Z.D.), Department of Cardiology, Shanghai Chest Hospital (Y.Y., L.D., M.Q., X.L.), and Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital (S.S., Z.Z
| |
Collapse
|
28
|
Patel B, Ismahil MA, Hamid T, Bansal SS, Prabhu SD. Mononuclear Phagocytes Are Dispensable for Cardiac Remodeling in Established Pressure-Overload Heart Failure. PLoS One 2017; 12:e0170781. [PMID: 28125666 PMCID: PMC5268479 DOI: 10.1371/journal.pone.0170781] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 01/10/2017] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Although cardiac and splenic mononuclear phagocytes (MPs), i.e., monocytes, macrophages and dendritic cells (DCs), are key contributors to cardiac remodeling after myocardial infarction, their role in pressure-overload remodeling is unclear. We tested the hypothesis that these immune cells are required for the progression of remodeling in pressure-overload heart failure (HF), and that MP depletion would ameliorate remodeling. METHODS AND RESULTS C57BL/6 mice were subjected to transverse aortic constriction (TAC) or sham operation, and assessed for alterations in MPs. As compared with sham, TAC mice exhibited expansion of circulating LyC6hi monocytes and pro-inflammatory CD206- cardiac macrophages early (1 w) after pressure-overload, prior to significant hypertrophy and systolic dysfunction, with subsequent resolution during chronic HF. In contrast, classical DCs were expanded in the heart in a biphasic manner, with peaks both early, analogous to macrophages, and late (8 w), during established HF. There was no significant expansion of circulating DCs, or Ly6C+ monocytes and DCs in the spleen. Periodic systemic MP depletion from 2 to 16 w after TAC in macrophage Fas-induced apoptosis (MaFIA) transgenic mice did not alter cardiac remodeling progression, nor did splenectomy in mice with established HF after TAC. Lastly, adoptive transfer of splenocytes from TAC HF mice into naïve recipients did not induce immediate or long-term cardiac dysfunction in recipient mice. CONCLUSIONS Mononuclear phagocytes populations expand in a phasic manner in the heart during pressure-overload. However, they are dispensable for the progression of remodeling and failure once significant hypertrophy is evident and blood monocytosis has normalized.
Collapse
Affiliation(s)
- Bindiya Patel
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Mohamed Ameen Ismahil
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Tariq Hamid
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Shyam S. Bansal
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Sumanth D. Prabhu
- Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Comprehensive Cardiovascular Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
- Medical Service, Birmingham VA Medical Center, Birmingham, AL, United States of America
- * E-mail:
| |
Collapse
|
29
|
Ong GSY, Young MJ. Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways. J Mol Endocrinol 2017; 58:R33-R57. [PMID: 27821439 DOI: 10.1530/jme-15-0318] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 11/06/2016] [Indexed: 12/22/2022]
Abstract
The mineralocorticoid receptor (MR) and mineralocorticoids regulate epithelial handling of electrolytes, and induces diverse effects on other tissues. Traditionally, the effects of MR were ascribed to ligand-receptor binding and activation of gene transcription. However, the MR also utilises a number of intracellular signalling cascades, often by transactivating unrelated receptors, to change cell function more rapidly. Although aldosterone is the physiological mineralocorticoid, it is not the sole ligand for MR. Tissue-selective and mineralocorticoid-specific effects are conferred through the enzyme 11β-hydroxysteroid dehydrogenase 2, cellular redox status and properties of the MR itself. Furthermore, not all aldosterone effects are mediated via MR, with implication of the involvement of other membrane-bound receptors such as GPER. This review will describe the ligands, receptors and intracellular mechanisms available for mineralocorticoid hormone and receptor signalling and illustrate their complex interactions in physiology and disease.
Collapse
Affiliation(s)
- Gregory S Y Ong
- Cardiovascular Endocrinology LaboratoryCentre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of MedicineSchool of Clinical Sciences, Monash University, Clayton, Victoria, Australia
| | - Morag J Young
- Cardiovascular Endocrinology LaboratoryCentre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of PhysiologySchool of Biomedical Sciences, Monash University, Clayton, Victoria, Australia
| |
Collapse
|
30
|
Ku HC, Lee SY, Wu YKA, Yang KC, Su MJ. A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats. JOURNAL OF VISUALIZED EXPERIMENTS : JOVE 2016:54818. [PMID: 28060255 PMCID: PMC5226336 DOI: 10.3791/54818] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Heart failure is one of the leading causes of death worldwide. It is a complex clinical syndromethat includes fatigue, dyspnea, exercise intolerance, and fluid retention. Changes in myocardial structure, electrical conduction, and energy metabolism develop with heart failure, leading to contractile dysfunction, increased risk of arrhythmias, and sudden death. Hypertensive heart disease is one of the key contributing factors of cardiac remodeling associated with heart failure. The most commonly-used animal model mimicking hypertensive heart disease is created via surgical interventions, such as by narrowing the aorta. Abdominal aortic constriction is a useful experimental technique to induce a pressure overload, which leads to heart failure. The surgery can be easily performed, without the need for chest opening or mechanical ventilation. Abdominal aortic constriction-induced cardiac pathology progresses gradually, making this model relevant to clinical hypertensive heart failure. Cardiac injury and remodeling can be observed 10 weeks after the surgery. The method described here provides a simple and effective approach to produce a hypertensive heart disease animal model that is suitable for studying disease mechanisms and for testing novel therapeutics.
Collapse
Affiliation(s)
- Hui-Chun Ku
- Graduate Institute of Pharmacology, College of Medicine, National Taiwan University
| | - Shih-Yi Lee
- Division of Pulmonary and Critical Care Medicine, Mackay Memorial Hospital,Mackay Medicine, Nursing and Management College
| | | | - Kai-Chien Yang
- Graduate Institute of Pharmacology, College of Medicine, National Taiwan University,Department of Internal Medicine, National Taiwan University Hosptial
| | - Ming-Jai Su
- Graduate Institute of Pharmacology, College of Medicine, National Taiwan University
| |
Collapse
|
31
|
Shen ZX, Chen XQ, Sun XN, Sun JY, Zhang WC, Zheng XJ, Zhang YY, Shi HJ, Zhang JW, Li C, Wang J, Liu X, Duan SZ. Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Atherosclerosis by Affecting Foam Cell Formation and Efferocytosis. J Biol Chem 2016; 292:925-935. [PMID: 27881672 DOI: 10.1074/jbc.m116.739243] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Revised: 10/15/2016] [Indexed: 12/12/2022] Open
Abstract
Mineralocorticoid receptor (MR) has been considered as a potential target for treating atherosclerosis. However, the cellular and molecular mechanisms are not completely understood. We aim to explore the functions and mechanisms of macrophage MR in atherosclerosis. Atherosclerosis-susceptible LDLRKO chimeric mice with bone marrow cells from floxed control mice or from myeloid MR knock-out (MRKO) mice were generated and fed with high cholesterol diet. Oil red O staining showed that MRKO decreased atherosclerotic lesion area in LDLRKO mice. In another mouse model of atherosclerosis, MRKO/APOEKO mice and floxed control/APOEKO mice were generated and treated with angiotensin II. Similarly, MRKO inhibited the atherosclerotic lesion area in APOEKO mice. Histological analysis showed that MRKO increased collagen coverage and decreased necrosis and macrophage accumulation in the lesions. In vitro results demonstrated that MRKO suppressed macrophage foam cell formation and up-regulated the expression of genes involved in cholesterol efflux. Furthermore, MRKO decreased accumulation of apoptotic cells and increased effective efferocytosis in atherosclerotic lesions. In vitro study further revealed that MRKO increased the phagocytic index of macrophages without affecting their apoptosis. In conclusion, MRKO reduces high cholesterol- or angiotensin II-induced atherosclerosis and favorably changes plaque composition, likely improving plaque stability. Mechanistically, MR deficiency suppresses macrophage foam cell formation and up-regulates expression of genes related to cholesterol efflux, as well as increases effective efferocytosis and phagocytic capacity of macrophages.
Collapse
Affiliation(s)
- Zhu-Xia Shen
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.,the Department of Cardiology, Jing'an District Centre Hospital of Shanghai, Huashan Hospital Jing'an Branch, Fudan University, Shanghai 200040, China.,the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Xiao-Qing Chen
- the Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
| | - Xue-Nan Sun
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.,the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Jian-Yong Sun
- the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Wu-Chang Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
| | - Xiao-Jun Zheng
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.,the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Yu-Yao Zhang
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.,the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Huan-Jing Shi
- the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Jia-Wei Zhang
- the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Chao Li
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.,the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China, and
| | - Jun Wang
- the Department of Cardiology, Jing'an District Centre Hospital of Shanghai, Huashan Hospital Jing'an Branch, Fudan University, Shanghai 200040, China
| | - Xu Liu
- the Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
| | - Sheng-Zhong Duan
- From the Laboratory of Oral Microbiology, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, School of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China,
| |
Collapse
|
32
|
Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction. Biochim Biophys Acta Mol Basis Dis 2016; 1863:2012-2018. [PMID: 27989961 DOI: 10.1016/j.bbadis.2016.10.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 09/29/2016] [Accepted: 10/26/2016] [Indexed: 02/07/2023]
Abstract
The prevalence of cardiac diastolic dysfunction and heart failure with preserved ejection, a major cause of morbidity and mortality in the western world, is increasing due, in part, to increases in obesity and type 2 diabetes. Characteristics of cardiac diastolic dysfunction include increased myocardial stiffness and impaired left ventricular (LV) relaxation that is characterized by prolonged isovolumic LV relaxation and slow LV filling. Obesity, insulin resistance and type 2 diabetes, especially in females promote activation of mineralocorticoid receptor (MR) signaling with resultant increases in oxidative stress, maladaptive immune responses, inflammation, and impairment of coronary blood flow and cardiac interstitial fibrosis. This review highlights findings from the recent surge in cardiac diastolic dysfunction research. To this end it highlights our contemporary understanding of molecular mechanisms of MR regulation by genetic, epigenetic and posttranslational modifications and resultant cardiac diastolic dysfunction associated with insulin resistance, obesity and type 2 diabetes. This review also explores potential preventative and therapeutic strategies directed in the prevention of cardiac diastolic dysfunction and heart failure with preserved ejection. This article is part of a Special Issue entitled: Genetic and epigenetic control of heart failure edited by Dr. Jun Ren & Yingmei Zhang.
Collapse
|
33
|
Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev 2016; 68:49-75. [PMID: 26668301 DOI: 10.1124/pr.115.011106] [Citation(s) in RCA: 197] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The mineralocorticoid receptor (MR) and its ligand aldosterone are the principal modulators of hormone-regulated renal sodium reabsorption. In addition to the kidney, there are several other cells and organs expressing MR, in which its activation mediates pathologic changes, indicating potential therapeutic applications of pharmacological MR antagonism. Steroidal MR antagonists have been used for decades to fight hypertension and more recently heart failure. New therapeutic indications are now arising, and nonsteroidal MR antagonists are currently under development. This review is focused on nonclassic MR targets in cardiac, vascular, renal, metabolic, ocular, and cutaneous diseases. The MR, associated with other risk factors, is involved in organ fibrosis, inflammation, oxidative stress, and aging; for example, in the kidney and heart MR mediates hormonal tissue-specific ion channel regulation. Genetic and epigenetic modifications of MR expression/activity that have been documented in hypertension may also present significant risk factors in other diseases and be susceptible to MR antagonism. Excess mineralocorticoid signaling, mediated by aldosterone or glucocorticoids binding, now appears deleterious in the progression of pathologies that may lead to end-stage organ failure and could therefore benefit from the repositioning of pharmacological MR antagonists.
Collapse
Affiliation(s)
- F Jaisser
- INSERM UMR 1138 Team 1, Cordeliers Research Center, Pierre et Marie Curie University, Paris, France (F.J., N.F); and University Paris-Est Creteil, Creteil, France (F.J.)
| | - N Farman
- INSERM UMR 1138 Team 1, Cordeliers Research Center, Pierre et Marie Curie University, Paris, France (F.J., N.F); and University Paris-Est Creteil, Creteil, France (F.J.)
| |
Collapse
|
34
|
Lother A, Hein L. Pharmacology of heart failure: From basic science to novel therapies. Pharmacol Ther 2016; 166:136-49. [PMID: 27456554 DOI: 10.1016/j.pharmthera.2016.07.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Accepted: 07/08/2016] [Indexed: 01/10/2023]
Abstract
Chronic heart failure is one of the leading causes for hospitalization in the United States and Europe, and is accompanied by high mortality. Current pharmacological therapy of chronic heart failure with reduced ejection fraction is largely based on compounds that inhibit the detrimental action of the adrenergic and the renin-angiotensin-aldosterone systems on the heart. More than one decade after spironolactone, two novel therapeutic principles have been added to the very recently released guidelines on heart failure therapy: the HCN-channel inhibitor ivabradine and the combined angiotensin and neprilysin inhibitor valsartan/sacubitril. New compounds that are in phase II or III clinical evaluation include novel non-steroidal mineralocorticoid receptor antagonists, guanylate cyclase activators or myosine activators. A variety of novel candidate targets have been identified and the availability of gene transfer has just begun to accelerate translation from basic science to clinical application. This review provides an overview of current pharmacology and pharmacotherapy in chronic heart failure at three stages: the updated clinical guidelines of the American Heart Association and the European Society of Cardiology, new drugs which are in clinical development, and finally innovative drug targets and their mechanisms in heart failure which are emerging from preclinical studies will be discussed.
Collapse
Affiliation(s)
- Achim Lother
- Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Heart Center, Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
| | - Lutz Hein
- Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany; BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany.
| |
Collapse
|
35
|
Sun JY, Li C, Shen ZX, Zhang WC, Ai TJ, Du LJ, Zhang YY, Yao GF, Liu Y, Sun S, Naray-Fejes-Toth A, Fejes-Toth G, Peng Y, Chen M, Liu X, Tao J, Zhou B, Yu Y, Guo F, Du J, Duan SZ. Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Neointimal Hyperplasia and Suppresses Macrophage Inflammation Through SGK1-AP1/NF-κB Pathways. Arterioscler Thromb Vasc Biol 2016; 36:874-85. [DOI: 10.1161/atvbaha.115.307031] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 02/19/2016] [Indexed: 01/08/2023]
Abstract
Objective—
Restenosis after percutaneous coronary intervention remains to be a serious medical problem. Although mineralocorticoid receptor (MR) has been implicated as a potential target for treating restenosis, the cellular and molecular mechanisms are largely unknown. This study aims to explore the functions of macrophage MR in neointimal hyperplasia and to delineate the molecular mechanisms.
Approach and Results—
Myeloid MR knockout (MMRKO) mice and controls were subjected to femoral artery injury. MMRKO reduced intima area and intima/media ratio, Ki67- and BrdU-positive vascular smooth muscle cells, expression of proinflammatory molecules, and macrophage accumulation in injured arteries. MMRKO macrophages migrated less in culture. MMRKO decreased Ki67- and BrdU-positive macrophages in injured arteries. MMRKO macrophages were less Ki67-positive in culture. Conditioned media from MMRKO macrophages induced less migration, Ki67 positivity, and proinflammatory gene expression of vascular smooth muscle cells. After lipopolysaccharide treatment, MMRKO macrophages had decreased p-cFos and p-cJun compared with control macrophages, suggesting suppressed activation of activator protein-1 (AP1). Nuclear factor-κB (NF-κB) pathway was also inhibited by MMRKO, manifested by decreased p-IκB kinase-β and p-IκBα, increased IκBα expression, decreased nuclear translocation of p65 and p50, as welll as decreased phosphorylation and expression of p65. Finally, overexpression of serum-and-glucocorticoid-inducible-kinase-1 (SGK1) attenuated the effects of MR deficiency in macrophages.
Conclusions—
Selective deletion of MR in myeloid cells limits macrophage accumulation and vascular inflammation and, therefore, inhibits neointimal hyperplasia and vascular remodeling. Mechanistically, MR deficiency suppresses migration and proliferation of macrophages and leads to less vascular smooth muscle cell activation. At the molecular level, MR deficiency suppresses macrophage inflammatory response via SGK1-AP1/NF-κB pathways.
Collapse
Affiliation(s)
- Jian-Yong Sun
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Chao Li
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Zhu-Xia Shen
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Wu-Chang Zhang
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Tang-Jun Ai
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Lin-Juan Du
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Yu-Yao Zhang
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Gao-Feng Yao
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Yan Liu
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Shuyang Sun
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Aniko Naray-Fejes-Toth
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Geza Fejes-Toth
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Yong Peng
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Mao Chen
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Xiaojing Liu
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Jun Tao
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Bin Zhou
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Ying Yu
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Feifan Guo
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Jie Du
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| | - Sheng-Zhong Duan
- From the Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China (J.-Y.S., C.L., Z.-X.S., W.-C.Z., T.-J.A., L.-J.D., Y.-Y.Z., G.-F.Y., Y.L., B.Z., Y.Y., F.G., S.-Z.D.); Shanghai Key Laboratory of Stomatology, Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine,
| |
Collapse
|
36
|
Garg R, Adler GK. Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders. Curr Hypertens Rep 2016; 17:52. [PMID: 26068659 DOI: 10.1007/s11906-015-0567-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Preclinical studies have convincingly demonstrated a role for the mineralocorticoid receptor (MR) in adipose tissue physiology. These studies show that increased MR activation causes adipocyte dysfunction leading to decreased production of insulin-sensitizing products and increased production of inflammatory factors, creating an environment conducive to metabolic and cardiovascular disease. Accumulating data also suggest that MR activation may be an important link between obesity and metabolic syndrome. Moreover, MR activation may mediate the pathogenic consequences of metabolic syndrome. Recent attempts at reversing cardiometabolic damage in patients with type 2 diabetes using MR antagonists have shown promising results. MR antagonists are already used to treat heart failure where their use decreases mortality and morbidity over and above the use of traditional therapies alone. However, more data are needed to establish the benefits of MR antagonists in diabetes, obesity, and metabolic syndrome.
Collapse
Affiliation(s)
- Rajesh Garg
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115, USA
| | | |
Collapse
|
37
|
Ayuzawa N, Nagase M, Ueda K, Nishimoto M, Kawarazaki W, Marumo T, Aiba A, Sakurai T, Shindo T, Fujita T. Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload–Induced Cardiac Injury. Hypertension 2016; 67:99-106. [DOI: 10.1161/hypertensionaha.115.06054] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 10/09/2015] [Indexed: 12/21/2022]
Affiliation(s)
- Nobuhiro Ayuzawa
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Miki Nagase
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Kohei Ueda
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Mitsuhiro Nishimoto
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Wakako Kawarazaki
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Takeshi Marumo
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Atsu Aiba
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Takayuki Sakurai
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Takayuki Shindo
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| | - Toshiro Fujita
- From the Division of Clinical Epigenetics, Research Center for Advanced Science and Technology (N.A., K.U., M. Nishimoto, W.K., T.M., T.F.), and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine (A.A.), The University of Tokyo, Tokyo, Japan; Department of Anatomy and Life Structure, Faculty of Medicine, Juntendo University, Tokyo, Japan (M. Nagase); CREST, Japan Science and Technology Agency, Tokyo, Japan (T.M., T.F.); and Department of
| |
Collapse
|
38
|
Lother A, Fürst D, Bergemann S, Gilsbach R, Grahammer F, Huber TB, Hilgendorf I, Bode C, Moser M, Hein L. Deoxycorticosterone Acetate/Salt–Induced Cardiac But Not Renal Injury Is Mediated By Endothelial Mineralocorticoid Receptors Independently From Blood Pressure. Hypertension 2016; 67:130-8. [DOI: 10.1161/hypertensionaha.115.06530] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Accepted: 10/12/2015] [Indexed: 12/23/2022]
Affiliation(s)
- Achim Lother
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - David Fürst
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Stella Bergemann
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Ralf Gilsbach
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Florian Grahammer
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Tobias B. Huber
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Ingo Hilgendorf
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Christoph Bode
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Martin Moser
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| | - Lutz Hein
- From the Department of Cardiology and Angiology I, Heart Center (A.L., I.H., C.B., M.M.), Institute of Experimental and Clinical Pharmacology and Toxicology (A.L., D.F., S.B., R.G., L.H.), Renal Division, Department of Medicine (F.G., T.B.H.), and BIOSS Centre for Biological Signaling Studies (T.B.H., L.H.), University of Freiburg, Freiburg, Germany
| |
Collapse
|
39
|
Montes-Cobos E, Li X, Fischer HJ, Sasse A, Kügler S, Didié M, Toischer K, Fassnacht M, Dressel R, Reichardt HM. Inducible Knock-Down of the Mineralocorticoid Receptor in Mice Disturbs Regulation of the Renin-Angiotensin-Aldosterone System and Attenuates Heart Failure Induced by Pressure Overload. PLoS One 2015; 10:e0143954. [PMID: 26605921 PMCID: PMC4659617 DOI: 10.1371/journal.pone.0143954] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 11/11/2015] [Indexed: 01/17/2023] Open
Abstract
Mineralocorticoid receptor (MR) inactivation in mice results in early postnatal lethality. Therefore we generated mice in which MR expression can be silenced during adulthood by administration of doxycycline (Dox). Using a lentiviral approach, we obtained two lines of transgenic mice harboring a construct that allows for regulatable MR inactivation by RNAi and concomitant expression of eGFP. MR mRNA levels in heart and kidney of inducible MR knock-down mice were unaltered in the absence of Dox, confirming the tightness of the system. In contrast, two weeks after Dox administration MR expression was significantly diminished in a variety of tissues. In the kidney, this resulted in lower mRNA levels of selected target genes, which was accompanied by strongly increased serum aldosterone and plasma renin levels as well as by elevated sodium excretion. In the healthy heart, gene expression and the amount of collagen were unchanged despite MR levels being significantly reduced. After transverse aortic constriction, however, cardiac hypertrophy and progressive heart failure were attenuated by MR silencing, fibrosis was unaffected and mRNA levels of a subset of genes reduced. Taken together, we believe that this mouse model is a useful tool to investigate the role of the MR in pathophysiological processes.
Collapse
Affiliation(s)
- Elena Montes-Cobos
- Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany
| | - Xiao Li
- Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany
| | - Henrike J. Fischer
- Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany
| | - André Sasse
- Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany
| | - Sebastian Kügler
- Department of Neurology, Center for Molecular Physiology of the Brain, University Medical Center Göttingen, 37073 Göttingen, Germany
| | - Michael Didié
- Institute of Pharmacology, University Medical Center Göttingen, 37073 Göttingen, Germany
- Department of Cardiology and Pneumology, University Medical Center Göttingen, 37073 Göttingen, Germany
- Partner site Göttingen, German Center for Cardiovascular Research (DZHK), 37073 Göttingen, Germany
| | - Karl Toischer
- Department of Cardiology and Pneumology, University Medical Center Göttingen, 37073 Göttingen, Germany
- Partner site Göttingen, German Center for Cardiovascular Research (DZHK), 37073 Göttingen, Germany
| | - Martin Fassnacht
- Endocrine and Diabetes Unit, Department of Internal Medicine I, University of Würzburg, 97080 Würzburg, Germany
| | - Ralf Dressel
- Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany
- Partner site Göttingen, German Center for Cardiovascular Research (DZHK), 37073 Göttingen, Germany
| | - Holger M. Reichardt
- Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany
- * E-mail:
| |
Collapse
|
40
|
Forrester SJ, Kawai T, O'Brien S, Thomas W, Harris RC, Eguchi S. Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System. Annu Rev Pharmacol Toxicol 2015; 56:627-53. [PMID: 26566153 DOI: 10.1146/annurev-pharmtox-070115-095427] [Citation(s) in RCA: 111] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Epidermal growth factor receptor (EGFR) activation impacts the physiology and pathophysiology of the cardiovascular system, and inhibition of EGFR activity is emerging as a potential therapeutic strategy to treat diseases including hypertension, cardiac hypertrophy, renal fibrosis, and abdominal aortic aneurysm. The capacity of G protein-coupled receptor (GPCR) agonists, such as angiotensin II (AngII), to promote EGFR signaling is called transactivation and is well described, yet delineating the molecular processes and functional relevance of this crosstalk has been challenging. Moreover, these critical findings are dispersed among many different fields. The aim of our review is to highlight recent advancements in defining the signaling cascades and downstream consequences of EGFR transactivation in the cardiovascular renal system. We also focus on studies that link EGFR transactivation to animal models of the disease, and we discuss potential therapeutic applications.
Collapse
Affiliation(s)
- Steven J Forrester
- Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania 19140;
| | - Tatsuo Kawai
- Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania 19140;
| | - Shannon O'Brien
- The School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland 4072, Australia
| | - Walter Thomas
- The School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland 4072, Australia
| | - Raymond C Harris
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
| | - Satoru Eguchi
- Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania 19140;
| |
Collapse
|
41
|
Abstract
Cardiac hypertrophy is characterized by complex multicellular alterations, such as cardiomyocyte growth, angiogenesis, fibrosis, and inflammation. The heart consists of myocytes and nonmyocytes, such as fibroblasts, vascular cells, and blood cells, and these cells communicate with each other directly or indirectly via a variety of autocrine or paracrine mediators. Accumulating evidence has suggested that nonmyocytes actively participate in the development of cardiac hypertrophy. In this review, recent progress in our understanding of the importance of nonmyocytes as a hub for induction of cardiac hypertrophy is summarized with an emphasis of the contribution of noncontact communication mediated by diffusible factors between cardiomyocytes and nonmyocytes in the heart.
Collapse
Affiliation(s)
- Takehiro Kamo
- From the Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (T.K., H.A., I.K.); and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan (H.A., I.K.)
| | - Hiroshi Akazawa
- From the Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (T.K., H.A., I.K.); and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan (H.A., I.K.)
| | - Issei Komuro
- From the Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (T.K., H.A., I.K.); and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Chiyoda-ku, Tokyo, Japan (H.A., I.K.)
| |
Collapse
|